|Bid||1.10 x 100|
|Ask||1.54 x 200|
|Day's Range||1.14 - 1.24|
|52 Week Range||0.93 - 1.47|
|PE Ratio (TTM)||3.70|
|Earnings Date||Aug 2, 2017 - Aug 7, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||2.15|
Shire plc (SHPG) announced that the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for Veyvondi to prevent and treat bleeding episodes and peri-operative bleeding in adults diagnosed with von Willebrand Disease.
GlaxoSmithKline plc (GSK) announced positive top-line results from a phase III revaccination study on its shingles vaccine candidate, Shingrix, in older patients.
Indivior PLC (INVVY) announced that a pivotal study (RB-US-13-0001) evaluating its candidate, RBP-6000, in patients with moderate-to-severe opioid use disorder (OUD) met its primary endpoint.